Indications and outcome in adult heart transplantation by Mariana Campos Lobo
 
 
 
 
 
 
 
 
 
 
 
MESTRADO INTEGRADO  
MEDICINA 
Indications and Outcome in Adult 
Heart Transplantation: A Review 
Mariana Campos Lobo 
M 
2019 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INSTITUTO DE CIÊNCIAS BIOMÉDICAS ABEL SALAZAR 
 
UNIVERSIDADE DO PORTO 
 
 
 
 
MESTRADO INTEGRADO EM MEDICINA 
 
 
 
Indications and Outcome in Adult Heart Transplantation: A Review 
 
 
 
 
 
 
Mariana Campos Lobo 
Endereço de correio electrónico: camposmariana@live.com.pt 
 
Mestrado Integrado em Medicina  
Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto  
 
Orientador: Prof. Doutor Humberto José da Silva Machado  
Professor Associado Convidado do Instituto de Ciências Biomédicas Abel Salazar  
Assistente Hospitalar Graduado Sénior de Anestesiologia do Centro Hospitalar do Porto  
Diretor do Serviço de Anestesiologia do Centro Hospitalar do Porto  
Adjunto da Direção Clínica do Centro Hospitalar do Porto 
 
JUNHO 2019 
 
 
i 
 
Resumo 
Introdução: O transplante cardiaco tem sido o tratamento gold standard para os doentes 
com insuficiência cardiaca em estadio terminal nos últimos anos. A mortalidade diminui nas 
últimas décadas e os doentes mostram uma melhoria da sua qualidade de vida, tendo uma 
sobrevida superior a 12 anos. O objective nesta revisão é dar a conhecerr alguns dos mais recentes 
avanços nos resultados a curto e a longo prazo, mais propriamente, na Vasculopatia Cardiaca do 
Enxerto, tempo de isquemia do enxerto, rejeição, suporte circulatorio mecánico e na 
imunossupressão e comprender como é possivel ajudar ainda mais estes doentes. 
Métodos: Foram pesquisados artigos no PubMed e foram acedidos ao report e guidelines 
do ISHLT, Eurotransplant, ACCF/AHA, UNOS e ESC tendo sido selecionados 81 artigos para esta 
revisão.  
Resultados: Nos últimos anos temos observado uma mudança na imunossupressão com 
o uso de Micofenolato de mofetil e Tacrolimus a aumentar e o uso de Ciclosporina e Azatioprina 
a diminuir. O Everolimus apresenta bons resultados na manutenção da função renal apesar de 
aumentar o risco de rejeição. A rejeição tem diminuido de incidência nos últimos anos mas o seu 
diagnóstico precoce e o follow up mostra-se incerto.  A Vasculopatia Cardiaca do Enxerto é a causa 
mais importante de comorbilidades a longo prazo sendo o diagnosticada através da angiografia 
coronária.  
Discussão: Nos últimos anos temos observado um aumento da idade do recipiente e do 
dador  o que pode afetar os resultados nestes doentes. É preciso ainda considerer esta mudança 
e o seu efeito na sobrevivência. É necessário mudar os criteria de exclusão de dadores já que as 
politicas atuais se mostraram bastante restritas. São necessário mais estudos sobre a etiologia da 
CAV, a sua prevenção e o diagnóstico de forma mais precoce. O uso de TCMS é importante no 
tratamento da disfunção do enxerto ou como ponte para o transplante  apresentando bons 
resultados. 
Conclusão: São necessários mais estudo sobre os doentes com indicação para transplante 
cardiac e sobre os novos agentes imunossupressores.  A vasculopatia cardiaca do enxerto e a 
rejeição necessitam de testes com maior precisão de diagnóstico para melhorar a sobrevivência 
dos doentes transplantados. 
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Abstract 
Introduction: Heart transplantation represents the gold standard treatment for patients 
with end-stage HF in the last years.  Mortality after transplant decreased in the last decade and 
patients show improvement in their quality of life. The objective is systematically reviewing the 
advances in the outcome, more exactly in Cardiac Allograft Vasculopathy, allograft ischemic time, 
rejection, mechanical circulatory support and immunosuppression and understand how we can 
help more these patients.  
Methods: PubMed and guidelines/report from ISHLT, UNOS, ACCF/AH, Eurotransplant, 
and ESC were researched, and 81 articles selected for this revision. 
Results: In the last years we observe a change in the immunosuppression with the use of 
Mycophenolate Mofetil and Tacrolimus instead of Ciclosporin and azathioprine. Everolimus 
presents great results in the manutention of renal function but increase the risk of rejection. In 
the last years the rejection becomes less common but the early diagnostic and the follow-up of 
patients still uncertain and difficult. The Cardiac Allograft Vasculopathy still the most important 
cause of late graft dysfunction and the best approach to diagnostic is the coronary angiography.  
Discussion: In the last years we observe an increase in the age of donors and recipient, 
what cause a change in the outcomes of this patient. Is important to consider that this change and 
the effect in the survivor. Is necessary to change the criteria of exclusion for non-use of donors 
because they are very restricted. Is necessary more study's about the Cardiac Allograft 
Vasculopathy to understand how we can prevent and make the correct diagnostic. The use of 
mechanical circulatory support is important for the treatment of graft dysfunction or to make the 
bridge until transplant with excellent outcomes.  
Conclusion: Is necessary more studies about the population that need a transplant and 
about the new option for immunosuppression. CAV and rejection need a more efficient test for 
diagnoses.    
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LVGLS: Left Ventricular Global Longitudinal Strain 
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MCS: Mechanical Circulatory Support  
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VAD: Ventricular Assist Device 
ECMO: Extracorporeal Membrane Oxygenation  
VA-ECMO: Veno-arterial Extracorporeal Membrane Oxygenation 
RVAD: Right Ventricular Assist Device 
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Introduction  
The first successful HT in humans occurred in 1967 in South Africa [1]. Fifty years later a 
lot has changed, becoming the gold standard treatment for patients with end-stage HF [2] and the 
only one that allows the recovery of approximately 70% of their quality of life [1]. In the 2018 
ISLHT report, transplant patients have an average life expectancy greater than 12 years, one of 
the biggest achievements of this procedure [1]. Despite a negative trend in the volume of 
transplants performed at the beginning of the 21st century, due to the decrease in organ supply 
and the increase in demand, the most recent data show a positive evolution in the last decade, 
with more than 3000 transplants in the USA in 2017. [1, 3-5] 
The latest ISLHT report in the USA observes an increase in older donors, an increase in the 
average age of recipients (55 years old), and in recipients over 70 years old without affecting long-
term survival. The main indications for HT in adults were non-ischemic dilated cardiomyopathies 
and ischemic cardiomyopathy, which had the highest long-term survival rates. Retransplantation 
continues to represent a small part (2.2%) of transplants and presents a low survival rate overall 
[1].  
According to 2017 Eurotransplant report, HT is the fourth most performed transplant, 
with donor numbers slightly declining during the last decade. The average age of the donor has 
risen in recent years and is close to 45 years old, somewhat different from the American reality 
[6, 7]. 
The main causes of mortality in these patients are graft dysfunction in the first 30 days, 
infectious causes in the first year and in the long-term, renal failure, and CAV. Rejection, ACR and 
AMR are also important factors in the prognosis of these patients, whose incidence has decreased 
due to immunosuppressive treatment. The risk of malignancies in the long-term is high, with an 
incidence of approximately 28%, the most common being skin neoplasia. Despite this, 
approximately 60% of the patients are not hospitalized during the first year and 80% between the 
second and fifth year of transplantation [1]. Immunosuppressive therapy has been one of the 
areas with the most advanced in recent years [1, 4, 8]. The most recent treatments include MMF 
or MPA and TAC, with a survival rate similar to older regimens with CsA and with fewer side effects 
[1, 9]. 
Despite major developments in surgical technique and diagnostic techniques, long-term 
survival is still limited by CAV, acute rejection, and the side effects of immunosuppressive therapy 
[4]. Increased donor and recipient age, increased co-morbidities and marginal donors, and 
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increased use of LVADs make it even more necessary to continue efforts to increase the survival 
of these patients [8, 10]. 
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Methods 
 
A search was performed on PubMed using the following keyword combinations: “Heart 
transplantation”, Mortality”, “adult”, “Practice Guideline”, “Patient Selection”, "Treatment 
Outcome" and “utilization”. 173 studies found using the mentioned keywords were selected to 
this revision. Inclusion criteria were: written in English or Portuguese, retrospective study, an 
observational study, prospective study, or guideline and published between 2009 and 2019. Just 
adult populations were accepted and 19 articles about congenital heart disease are excluded 
because the main manifestations are in pediatric age. 39 articles are excluded because they are 
duplicate in the research. 71 articles after the read of abstract and title are excluded because they 
cover topics not included in this revision (multi-transplant, therapy for end-stage HF, recipient 
treatment, waiting list, treatment for CAV and rejection, another disease like amyloidosis and 
adhesion to therapeutic).  10 relevant papers cited in the selected articles were added to the 
group. 17 guidelines are included from ISHLT, ACF/AHA, Eurotransplant, OPTN/SRTR and Society 
of critical care medicine, ending up with 81 articles analyzing in this review. 
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Results 
1. Indications 
HT is the most commonly used therapy for patients with end-stage HF when they no longer 
respond to medical therapy [2]. Lenneman et al and Oliveira et al evaluated the patients 
undergoing transplantation for dilated cardiomyopathy due to chemotherapy, a growing 
population, consisting of young female patients with a higher prevalence of breast neoplasia and 
leukemia [11, 12]. A 10-year survival was higher (P = 0.026) in the Lenneman study [11] and the 
same in the Oliveira study (P = 0.19) [12]. There was no increase in mortality due to neoplasia or 
its recurrence. The infection rate was higher in the Oliveira study (P = 0.006) [12]. These patients 
presented a greater need for right ventricular assist devices prior to transplantation (P = 0.0021) 
and longer ischemia time (P <0.001) due to their use [12].  
Patients with HF are only indicated for transplantation at an advanced stage, which often 
makes the transplant difficult. With this idea, Lund et al evaluated the use of a screening test to 
identify patients eligible for transplant (SEE-HF, ScrEEning for Advanced Heart Failure) in patients 
undergoing resynchronisation therapy and with stage III and/or IV HF NYHA and EF <40%, with 
1.5% of patients screened being indicated for transplantation and LVAD [13]. 
The existence of available donors is a determining factor in HT, and in recent years the 
number of donors has increased [5]. Bombardini et al evaluated the use of stress 
echocardiography to select donors aged >55 or with cardiovascular risk factors and the survival 
rate after 1 year was 93% and after 3 years 37 of the 43 recipients were alive [14].  
In recent years, we have witnessed an increase in the use of marginal donors. Aliabadi-
Zuckermann et al observed that the 3-year survival rate in Vienna was 79% and the survival of 
organs accepted by other centres after being rejected by Vienna for non-quality reasons and 
quality reasons was 73% and 63% (P <0.001), with higher survival in the case of positive virology 
(77%), high catecholamines (68%), long ischemic time (71%) or low ejection fraction (68%) and 
lower in the case of hypernatremia (46%), cardiac arrest (21%) and valvular pathology (50%) [15]. 
In an attempt to improve the selection of recipients, Weiss et al created a score, IMPACT 
(Table 1), with 12 recipient variables, up to 50 points, which is associated to mortality after the 
first year [16]. According to this score, survival at 1 year with a score between 0 and 2 was 92.5%, 
between 7 and 9 points was 86.3%, higher than 10 was 74.9% (P <0.001) and with scores higher 
than 20, mortality was greater than 50% [16]. Trivedi et al created a score (Table 2) for mortality 
based on the donor and the recipient [17]. Based on this score, low-risk recipients (score = 1) were 
combined with high-risk donors (score ≥3) and survival at 1 and 5 years of age was 89% and 74%, 
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respectively, and the combination of high-risk donors and recipients (score ≥5) had a survival rate 
of 62% and 49% [17]. 
2. Outcome 
Mortality after transplant decreased in the last decade [5], is one of the major achievements 
of HT. Patients show great improvement in their quality of life, however, infections, neoplasias, 
chronic renal disease, and CAV continue to interfere with long-term survival [18].  
Organ preservation evolved greatly, and OCS, a new ex vivo perfusion platform, was studied 
by Ardehali et al in a PROCEED II study and by Chan et al in a retrospective study. Survival at 30 
days (P = 0.45) [19] and at 2 years (P = 0.38) [20], rejection rates and cardiovascular events were 
similar to the cold storage group [19, 20]. The mean total preservation was higher and the cold 
ischemia time was lower [19, 20]. 
Immunosuppressive therapy has changed greatly in recent years, and the study by Zijlstra 
et al observed that, between 2000 and 2013, immunosuppressive therapy was TAC and/or MMF, 
received statins early on and renal function remained stable over 5 and 10 years (P = 0.001 and 
0.002). The transplant group from 1984-1999 had younger patients, a lower donor percentage 
>50 years, and an immunosuppressive treatment consisting of CsA and AZA. Despite the increase 
in donor and recipient age and comorbidities, the most recent era presented a higher survival rate 
at 10 years (80% vs 60%) [9].  
A randomized clinical study, SCHEDULE, by Andreassen et al, evaluated the introduction 
of EVR between the 7th and 11th week in maintenance therapy with MMF and steroids. EVR 
presented higher GFR after the first year (P <0.001), reduction in the incidence of CAV (P = 0.003), 
lower MIT (P = 0.03), lower incidence of CMV infection (P <0.001), but higher incidence of acute 
rejection (P = 0.03) [21]. This study was continued for a further 3-year period and GFR was higher 
(P <0.001) and MIT lower (P = 0.019), with EVR and the incidence of CAV and acute rejection similar 
to CsA group (P = 0.104, P = 0.483) [22]. Authen et al evaluated the effect of EVR and CsA on quality 
of life before, 12 and 36 months after HT and found no differences between immunosuppressive 
agents and the 3 questionnaires (p<0,01) [23]. A retrospective substudy of SCHEDULE by Nelson 
et al in 2017 found that GFR was greater in the EVR group at 1 and 3 years (P = 0.0004 and P = 
0.03), as was the ratio of albumin/creatinine in urine (ACR) (P = 0.002) [24]. Helmschrott et al 
observed that eGFR, serum creatinine and the incidence of ACR were similar between mTOR/CsA 
and mTOR/TAC (P >0.05), and repeated measurement of eGFR showed a similar decrease in the 2 
groups [25]. Kaczmarek et al observed that survival at 5 years was similar between TAC/MMF, 
SIR/MMF and TAC/SIR (P = 0.31, P = 0.47, P = 0.86) [26]. The rejection free period was lower such 
as the incidence of CAV in SIR/MMF [26]. The longest free period for CMV infection occurred with 
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TAC/SIR (89.7%) [26]. GFR remained stable in SIR/MMF (P = 0.045) [26]. The discontinuation of 
medication was higher with TAC/SIR (P = 0.034) and with SIR/MMF (P = 0.003) [26]. Guethoff et al 
observed that survival at 1, 5 and 10 years was similar between TAC/MMF and CsA/MMF (P >0.05), 
however, the free period without AR was higher with TAC/MMF (P = 0.004), just as the CAV-free 
period at 5 and 10 years (P = 0.003) [27]. In a randomised prospective study from 2015, Guethoff 
et al found that the rejection-free period and incidence of CAV was not different between low-
TAC/SIR and TAC/MMF (P = 0.100, P = 0.922), just as the value of creatinine and survival at 5 and 
8 years (P = 0.957, P = 0.957, P = 0.138) [28]. Kobashigawa et al showed that after 1 year, the 
increase in MIT was lower in EVR (P <0.001), as was the incidence of CAV (P = 0.018) and the 
incidence of CMV infection (P <0.001) compared to MMF [29]. Watanabe et al studied the 
replacement of MMF with EVR 2 years after HT and EVR presented a low increase in plaque volume 
(P = 0.004) and a decrease in lumen volume (P = 0.017) [30].   
Rejection is one of the problems that continue to interfere with patient survival [8]. 
Soderlund et al showed that ACR ≥2R in the 1st year is more common in the EMB per clinic (P 
<0.05) between 1988-1999 (P <0.05) and between 16-52 weeks (P <0.05) [31] and that ACR≥2R 
after the 1st year is also more common in the EMB per clinic (P <0.05) [32]. Imamura et al observed 
that patients with PRA + (P = 0.042) presented LR earlier [33]. The risk factor for LR was PRA + (P 
= 0.020) whereas for ACR it was sex mismatch (P = 0.042) [33]. Farrero et al observed that patients 
with DSA post-transplant had a higher incidence of ACR (P < 0.001) and AMR (P <0.001), especially 
in C1q + patients [34]. Survival in DSA + was lower due to high acute rejection mortality (P = 0.031) 
but there was no difference between the C1q + and – groups [34]. In 2015, Kobashigawa et al 
evaluated, in the IMAGE trial, the use of GEP instead of EBM and, after 18 months, no differences 
were observed in the level of mortality, retransplantation rate, rejection, graft dysfunction (P = 
0.44), MIT increase (P = 0.944), echocardiographic study and satisfaction level [35]. 
The use of MCS has been increasing in the last years, whereas VAD is the most used [1]. 
Tran et al observed that the use of ECMO due to graft dysfunction results in lower mortality (P = 
0.02), while patients requiring CPR have a high mortality rate (P = 0.01), especially when CPR> 30 
min (P = 0.001) and EF> 35% (P = 0.001) [36]. Tchantchaleishvili et al showed that the use of MCS 
decreased survival at 30 days (P = 0.01) and at 1 year (P <0.001), with RVAD or VA ECMO presenting 
the highest survival rates (P = 0.055) [37]. Johnston et al 2016 created a score, TRIP-MCS (table 3), 
to assess mortality in the first year after HT, after the use of MCS [38]. It is a score of up to 57 
points, with 13 donor’s and recipient’s variables. The first-year mortality rate predicted through 
this model was similar to the observed values (P <0.001), with one point increasing mortality by 
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8.3% [38]. Patients were divided into risk groups: low (0 to 10), intermediate (11 to 20) and high 
(> 20) with a mortality of 8.6%, 12.8% and 31%, respectively [38]. 
CAV is one of the major causes of mortality in the long-term [1] and its diagnosis is done 
with CA [39]. Okada et al observed that patients with increased ASP had a higher incidence of ACR 
(P = 0.006), such as plaque volume (P = 0.07) and an even higher mortality and retransplantation 
rate (P = 0.0005) [40].  In 2016, Yang et al evaluated several physiological indicators of coronary 
heart function such as FFR and IMR, whereas an IMR ≥20 after 1 year (P = 0.01) and FFR <0.90 (P 
= 0.03) shortly after transplantation are predictors of mortality in the long-term (P = 0.009) [41]. 
The decrease in IMR in the first year post-transplant is related to increased patient survival (P = 
0.03) [41]. In 2016, Clemmensen et al found, in a prospective study, that the LVGLS ultrasound 
marker is a good predictor of MACE in patients with or without CAV (P <0.0001, P <0.05) and of 
mortality (P <0.0001) [42]. LVFP is a predictor of MACE in patients with CAV (P <0.01) [42]. The 
combination of both markers makes them predictors of MACE and mortality (P <0.0001, P 
<0.0001) [42]. In 2017, Clemmensen et al evaluated the coronary microcirculation through OCT 
and the area of the intima increased (P <0.0001), the lumen decreased in only 2% (P <0.01), the 
LFP increased more than 5 times (P <0.001) as well as the bright spots (P <0.001), while plaque 
lipids (P = 0.78) and calcification (P = 0.37) remained stable [43]. In another study, Clemmensen et 
al observed that LFP was the most prevalent CAV lesion in the OCT and is related to its severity (P 
<0.01) [44]. LFP (P <0.0001) and bright spots (P <0.001) were predictors of NFCP and were also 
combined (P <0.0001) [44]. Rutz et al studied the contrast echocardiography and its markers, rBV, 
indicative of microvascular density, lower in the group with CAV (P = 0.0157) and β, indicative of 
coronary conduction, higher in patients with CAV (P = 0.0410) [45]. rBV is inversely related to the 
intimal thickening detected by the IVUS and an rBV <0.14 predicts a CAV, with a sensitivity of 75% 
and a specificity of 90% (P = 0.004) [45]. Sade et al observed that 9 patients with CAV were 
diagnosed through CA, 10 through DSE and 14 through CFR [46]. DSE has a sensitivity of 55.6% 
and a specificity of 64.3%, a PPV of 50% and an NPV of 69.2% [46]. CFR has a sensitivity of 100%, 
a specificity of 64.3%, a PPV of 64.3% and an NPV of 100% [46]. The combination of both allows 
an increase in specificity to 87.2% [46]. In the study by Peled et al, 47% of patients received aspirin 
during the first month and had a lower incidence of CAV (P <0.001) and mortality (P <0.0001) [47]. 
The use of aspirin decreased mortality by 84% (P <0.001) and CAV by 68% (P <0.0001) [47]. The 
risk factors associated with CAV and mortality were CMV (P = 0.02), smoking (P = 0.008) and 
history of rejections (P = 0.0038) [47]. In the study by Kim et al, 49% of patients received aspirin 
up to 6 months post-transplant and the incidence of CAV was lower in this group (P = 0.04) [48]. 
Tremblay et al observed that patients between 1983-1998 presented a higher incidence of 
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smoking, renal dysfunction, alteration of levels of LHDL, higher incidence of rejection, young 
donors, CA (P <0.001) and prevalence of CAV (P = 0.005) [49]. Independent factors for progression 
of CAV were the young age of the recipient (P = 0.013) and early-stage transplantation (P = 0.049) 
[49].  
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Discussion 
1. Indication 
The assessment of patients with end-stage HF for their selection for transplantation should be 
done by a multidisciplinary team and based on the guidelines [4]. Both AHA [2] and ESC [50] 
present indications for HT. But in 2016, ISHLT, the world’s largest transplant organization, 
presented an update on indications and contraindications for transplant candidates (Table 4) [51, 
52] and these are the most commonly used. Fragility was included in these guidelines due to its 
high prevalence in the elderly population, given that it is associated with the gradual and natural 
physiological decline that occurs with aging [53-55], aggravates the prognosis, the results with the 
use of LVAD and the need for hospitalizations [54]. Its presence may contraindicate the 
performance of the transplant [51, 55]. There is little consensus regarding the evaluation method 
and the type of tools that should be used in patient assessment [51]. Another change is the 
reference that highly sensitized patients have a high priority on the waiting lists due to increased 
difficulty in finding a compatible donor [51], due to the increased risk of rejection [56].  
Despite high early mortality and low long-term survival [1, 51, 57, 58], retransplantation is an 
option for patients with chronic symptomatic or asymptomatic CAV with LV or graft dysfunction 
and no evidence of acute rejection [51, 58] or, in the case of primary graft failure as well [58]. In 
the 2014 ISHLT report on the subject, and although the number of retransplantations remains 
constant since 1982 (between 2% and 4%), it is highlighted that the increase in the long-term 
survival of recipients increases the likelihood of future retransplantation [58], whereas these 
results need to be improved.  
Both the donor and the recipient have characteristics that are different from those of 50 years 
ago, the median age of the recipient went from 40 years old in 1982 [57] to 55 years old in 2018, 
with an increase in recipients >60 years old [1]. Although the age of the recipient is related to 
increased mortality [57], after an individual risk assessment, the recipients >70 years old may 
undergo transplantation [59-61]. In the Zilstra study in the Netherlands, it was observed that, 
despite the increase in the recipient’s age, long-term survival also increased, due to improved 
long-term care [9]. With the increase of the recipient’s age and the incidence of end-stage HF, 
transplantation is increasingly important as the only therapeutic option with gain in quality of life 
for the patient.  
In the 2016 review, Bianco et al referred an increase in recent years of transplants by CCMP 
or RT-CMP, whereas these pathologies have gained greater recognition and a correct classification 
[62]. CCMP affects approximately 10% of patients and 2-4% of patients will present end-stage HF 
[12] and, according to UNOS, between 1987 and 2011, 0.8% of transplants had CCMP and RT-CMP 
10 
 
[62]. The increase in cancer and drug exposed survivors contributes to the increase in transplanted 
patients [11, 12, 62]. Anthracyclines, cyclophosphamide, trastuzumab and tyrosine kinase 
inhibitors are examples of agents that cause cardiomyopathy [12]. The higher risk of 
cardiomyopathy occurs in breast cancer, which accounts for the greater number of young and 
female patients in the studies by Oliveira and Lenneman [11, 12]. There is no free interval defined 
between cancer and transplantation [11, 63] and, according to the ISHLT guidelines, cancer is no 
longer a contraindication for transplantation [52]. Although OHT has been questioned in the past 
due to the risk of recurrence and infections, today it is a safe therapeutic option for these patients 
[12]. Due to the increase in cancer survivors, it is important to pay more attention to these 
patients, since they require special attention due to poorer results with VAD due to the thoracic 
adhesions.  
Patients are referred to transplantation at an advanced stage, and the use of a screening test 
is a promising approach. Most patients undergoing transplantation or LVAD are in stage IV, the 
inclusion of the NYHA classification and the EF value increased the diagnostic value of the Lund 
screening [13]. It allows the identification of patients who may benefit from HT or LVAS at an 
earlier stage, even before the symptoms worsen, alert the physician to the possible benefit of 
transplantation in the patient and work with the patient on the advantages of transplantation 
[13]. 
The stagnation in the number of donors, in relation to the number of recipients [1] led to the 
use of marginal donor organs [14], increasing the pool of donors and the number of 
transplantations performed [64]. Marginal or high-risk donors are donors of advanced age (over 
40 years old) or with cardiovascular risk factors [14, 65]. It is necessary to find a balance between 
the expansion of donor selection criteria and maintenance of the high survival of the recipients 
and the risk of graft dysfunction [64]. In a report on the use of marginal donors in France, 
limitations for the use of these donors are referred (Table 5) [64]. The use of donor organs 
between ages 40 and 55 presents a greater benefit, increased survival, in relation to the risk of 
CAD and LVH [65], which means their organs may be used [64]. The transthoracic echocardiogram, 
a non-invasive exam, evaluates cardiac motility and the LVEF of the graft [64]. According to the 
Bombardini et al study, the use of dipyridamole or dobutamine echocardiography allows the 
exclusion of grafts with motility alterations, both during rest and in stress [14]. The good medium-
term results for survival and death similar to “normal” donors [14] are in line with the widening 
of donor age to >55 years as the exclusion criterion in the USA in 2015 (table 6) [66]. One of the 
consequences of the use of older donors is the increasing diagnosis of donor CAD [65]. Donor CAD 
increases the risk of early graft failure [14] but not of CAV [67]. It is diagnosed through CA (stenosis 
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≥50%) or IVUS (≥0.5 mm) after transplantation [67]. In the USA, CA is recommended in all donors 
over 40 years of age or donors with risk factors [66]. Thus, the increased use of marginal donors 
should be done with caution, and further studies are needed to evaluate the use of donors 
between the ages of 55-70 in the long-term [64]. 
Weiss and Trivedi created a score for mortality, both of which allow correct allocation of 
organs [16, 17]. Patients with a score of ≥20 on the IMPACT score present high mortality [16] and 
do not benefit from the use of marginal donors. The same line of thought can be applied to the 
Trivedi score, but with the advantage that it included data from the donor and allows a search for 
the best donor for the recipient in question, a very useful tool in the case of high-risk recipients, 
where it is possible to decrease the waiting period [17]. Through the Trivedi score, it is also 
possible to deduce that the use of high-risk donors in low-risk recipients is safe, which is important 
for better allocation of organs, without impairing long-term survival [17].  
In recent years we have witnessed an expansion of organ acceptance criteria, both in the 
USA [66] and in Europe [15], as was observed in the Aliabadi-Zuckermann study in a center in 
Vienna. This center presented a lower organ acceptance rate (31.8%) than the European medium 
(38%), due to its stricter selection criteria [15]. This study showed that the center could broaden 
its donor acceptance policy without affecting short and long-term survival [15]. Positive virology, 
high level of catecholamines and low LVEF, all the factors related to the donor had the highest 
survival rates in other centers, which means that these should be the criteria to be changed [15]. 
The fact that all the factors are related to the donor, show the greater importance of the recipient 
in post-transplantation results [64].  
2. Outcome 
2.1 Allograft Ischemic time 
Addressed by ISLHT in 2017, allograft ischemic time refers to the period in which the graft 
does not present blood supply, from the cutting of the aorta to the coronary reperfusion in the 
recipient [3]. In 2017, its value was 3.2 hours in the USA and >4 hours in Europe, and it has been 
decreasing since 2000 [3]. A value of >4h is associated with lower survival, both in the short and 
long-term, but with higher mortality risk in the immediate post-transplantation period [3] and is 
associated with PGD [68]. High values are associated with the risk of rejection, but unrelated to 
CAV [3] and are acceptable in younger recipients [3]. 
Despite the evolution of organ preservation in recent years [8, 19, 20] cold storage, where the 
organ is maintained in a cold environment, is still the most used technique [19, 20]. It presents a 
higher risk of allograft ischemic time, a longer cold ischemia time [19, 20]. Another technique, ex 
vivo perfusion, of which the Organ Care System (OCS) platform is an example, allows transport in 
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an environment similar to the normal physiological state (continuous perfusion of nutrients and 
oxygen in a warm environment that maintains the heartbeat) [19, 20]. The need for graft 
instrumentation and evaluation increased the total mean time for preservation, the time elapsed 
since the heart stopped until the reperfusion in the recipient but decreased the cold ischemic 
time, the period during which the organ remains in a cold environment, in the studies by Chan 
and Adehali [19, 20]. Survival at 30 days [19] and at 2 years [20] was similar to cold storage. The 
rejection of 5 organs in the Ardehali study [19] raises some questions regarding the OCS, due to 
the risk of lactate accumulation. Although it is not statistically important, the incidence of CAV is 
lower in the OCS group due to the shorter cold ischemic time [20], and further studies on the long-
term results of this technique are required. In spite of this, the use of OCS allows the increase of 
the donor pool, the resuscitation of unacceptable organs, pre-transplant pharmacological or 
genetic use, the increase in organ availability and transportation between long distances [19]. 
With the use of marginal donors, the use of LVAD and previous cardiac surgeries on the rise, 
allograft ischemic time will increase [3, 34], and the OCS will be able to overcome this obstacle.  
2.2 Immunosuppression  
It encompasses induction therapy that covers the immediate post-operative and 
maintenance therapy that accompanies the patient throughout his/her life [4]. Induction therapy 
is only used in 50% of patients [1] and can be done with polyclonal antibodies, more specifically 
ATG in patients at high risk for rejection [8]. The maintenance therapy used in approximately 75% 
of cases in 2018 is TAC/MMF and corticosteroids during the first year, a triple regimen [1, 30], 
presenting low rejection rates and the improvement of renal function, which is the regimen 
recommended by ISHLT [8]. PSI can replace CNI starting at 6 months to reduce the risk of renal 
injury, and should not be introduced before due to the risk of non-healing of the surgical wound 
[8].  
In recent years, the use of the CsA+AZA+prednisolone regimen decreased and the use of 
TAC+prednisolone+MMF increased, as observed in several studies [9, 31, 49]. The use of TAC is 
beneficial in relation to CsA, presenting a lower incidence of AR and CAV, without increasing 
overall survival [27]. ISHLT is consistent with these results and recommends the use of TAC instead 
of CsA [8]. The use of MMF, purine synthesis inhibitor [26, 29], presents greater survival when 
compared to AZA, lower AR rates [27] and no effects on renal function [26]. The use of MMF can 
cause diarrhea and leukopenia [25].   
TAC and CsA are CNI [27] and, although they decrease the rate of AR [28], they present 
nephrotoxic effects, which decrease long-term survival [21-27]. In 2004, with the introduction of 
mTOR, EVR, and SIR, with antiproliferative effects (PSI) on hematopoietic and non-hematopoietic 
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cells [29] and neutral effect on renal function [21, 22, 24-26, 28]. These drugs decrease the risk of 
CMV infection and malignancies [25, 26, 69]. The use of mTOR is promising, by reducing the 
nephrotoxic effect of CNI, but is associated with the appearance of proteinuria as reported in 
Nelson’s study and his use is contraindicated in patients with prior proteinuria due to the failure 
rate [24]. This study found no relationship between the value of GFR and proteinuria and the 
absence of regression of proteinuria with IECA or ARB show that the aldosterone or renin does 
not interfere in this framework [24]. The use of a regimen without CNI in high-risk patients does 
not require induction therapy due to the risk of rejection [26]. The elimination of CNI increased 
lateral effects such as poor healing of the surgical wound or pleural effusions [21, 22, 26], as 
previously mentioned in the ISHLT guidelines [8]. Patients recover their quality of life with the 
transplant but, due to the side effects of immunosuppressive therapies and the complications of 
the transplantation, they will present a lower quality of life than the general population [23]. 
Despite the benefits at the renal level, EVR may be associated with more severe psychological 
effects due to the risk of rejection [23].  
The SCHEDULE study showed that the use of EVR introduced early on improves renal 
function and reduces CAV, in both the short and intermediate term [21, 22]. Despite increased 
rejection in the first year, its use may bring long-term benefits [21, 22]. Given that only low-risk 
patients were used in these studies since high-risk patients were excluded, the early use of EVR is 
safe in this group [22]. The Kaczmarek study revealed that treatment without CNI (SIR/MMF) 
maintains GFR during 5 years and increases the CAV-free period, but is poorly tolerated by the 
patient and increases the incidence of rejection [26]. The Imamura study found no association 
between EVR in the absence of CNI and late ACR [33], such as the Kaczmarek study [26]. Patients 
with side effects caused by CNI or MMF, with episodes of rejection, CAV or malignancies may 
benefit from the use of mTOR with low doses of CNI, which reduces CNI nephrotoxic potential and 
the risk of rejection of mTOR, however, the Helmscroot study showed no difference in eGFR and 
ACR between mTOR/CsA and mTOR/TAC [25]. One disadvantage of this study is that it did not 
indicate that mTOR was used, nor when it was introduced. In 2015, Guethoff showed that low-
TAC/SIR showed no difference in the incidence of ACR, CAV, renal function and survival with 
TAC/MMF, and the benefit in renal function was not maintained during the 8 years [28]. This study 
had an 8-year follow-up, the largest of the studies with mTOR/mTOR, thus allowing the evaluation 
of their long-term effects. Unlike the SCHEDULE study, it did not present any benefit in renal 
function, just as the Helmscroot study, which shows that the protective effect of mTOR is not 
maintained in the long-term. These studies use different methods to evaluate renal function, from 
serum creatinine to GFR and eGFR, which makes it impossible to extrapolate their results and 
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compare them. Further clinical trials are important, in order to elucidate the long-term effects of 
mTOR despite its good short-term results. Studies in this field involve small populations with the 
intensification of studies such as Guethoff and Kaczmarek with mTOR, which present high 
discontinuation rates due to lateral effects, making it difficult to draw conclusions from these 
studies. Another point still to be clarified is when the introduction of mTOR should be made, and 
a balance must be found between the risk of rejection and the reduction of CNI exposure. 
2.3 Rejection 
Its strict monitoring is done through EMB during the first year [8]. After this high-risk period, 
high-risk patients should perform an EBM every 6 months, otherwise, the patient does not justify 
its performance and may opt to use ventricular evoked potentials [8]. 
Sensitization, presence of autoantibodies, decreases compatibility with the donor, or 
post-transplantation (DSA) is associated with rejection [33], CAV and decreases long-term survival 
[56]. Female recipients are more likely to be previously sensitized, due to pregnancies and a higher 
incidence of autoimmune diseases [33]. The use of LVAD or previous surgeries increases the risk 
of sensitization [70]. PRA value >10% detects the risk of sensitized patients and should be 
performed prior to transplantation [56, 71]. In 2018, a new recipient allocation system (table 7) 
entered into force at UNOS, which included 6 zones, one of them for sensitized recipients [72], to 
decrease the waiting list of these patients and following the ISHLT recommendations [5]. 
In the Soderlund study, the highest number of EBM was recorded between 1988 and 1999, 
which can be explained by the development of induction and maintenance immunosuppressive 
therapy [31]. The highest number of EMBs was between week 16 and 52, due to poor therapeutic 
control and decreased use of immunosuppressants during this phase [31, 33] indicating that this 
period requires more vigilance through EBM. According to Soderlund, high-risk patients (patients 
with sex mismatch and history of ACR in the first year) should perform EMBs periodically [32], as 
recommended by the ISHLT guidelines [8]. The Imamura study is in line with this suggestion, 
showing that patients with a history of ACR in the first year and PRA + present a high risk of LR, 
requiring greater follow-up with EBM [33]. Patients without ACR and PRA - may see the number 
of EMBs reduced, thus avoiding the complications associated with this technique [33].  
GEP is a non-invasive and economical procedure, based on the analysis of 20 genes [35]. 
Based on previous studies, a value ≥30 between the 2nd and 6th month and ≥34 after 6 months is 
indicative of ACR, leading to the performance of a biopsy [35]. In the Kobashigawa study, no 
differences in ACR, survival, and IVUS parameters between the use of GEP and EBM post-
transplantation were found [35]. This study showed the efficacy and safety of GEP in low-risk 
populations, given that high-risk patients were excluded from this study [35]. A high number of 
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biopsies lead to an increase in side effects (hemorrhage, pericardial perforation) because it is an 
invasive technique, and GEP is important for stratifying patients according to the risk of rejection 
and to decrease the use of EBM [35]. However, more long-term studies on the use of GEP are 
needed.   
In the Farrero study, the existence of a high immune response explains the high rejection 
mortality rate in the group with de novo DSA [34]. This study also showed that a blood test looking 
for autoantibodies may stratify patients according to their risk for rejection [34]. It was the first 
study to show the importance of C1q, which assesses the ability of antibody complement binding 
to DSA and AMR [34], thus being another tool for monitoring patients and improving their long-
term follow-up and monitoring, and decreasing the use of EBM.  
ACR involves a cellular response and its incidence decreases thanks to immunosuppressive 
therapy and improved diagnosis [8, 56]. It continues to account for 10% of mortality in the 1st year 
[31], decreased overall survival [32, 33] and the main cause of graft dysfunction during the first 
year post-transplantation [26]. ACR has a higher incidence during the first 3 months post-
transplantation and after the first year of transplantation, the risk decreases progressively without 
ever disappearing [31], as was observed in the Soderlund study [32]. Risk factors are sex mismatch, 
CMV infection, HLA-mismatching, young recipients and donors and long ischemia time [31]. The 
existence of DSA also increases the risk of ACR, given that these antibodies act as a trigger [34]. 
Insufficient immunosuppressive therapy also increases the risk of ACR [8]. CsA and TAC are the 
most efficient in preventing ACR episodes whereas early weaning, before 6 months, increases 
rejection rates [69]. 
AMR results from the existence of autoantibodies against class I and II HLA in the graft, 
activating the complement or the mTOR pathway in the immunoglobulin membrane [56]. In 
recent years, new antibodies have been implicated in this process, such as the anti-angiotensin 
type 1 receptor antibody. The appearance of these autoantibodies results from transient ischemia 
or trauma during surgery, leading to an autoimmune response after graft antigen release. 
Antibodies act in synergy creating a “perfect storm” and the appearance of AMR [73, 74]. AMR is 
an indicator of poor prognosis and is more common in sensitized patients [70]. Its study can be 
done through immunohistochemistry using paraffin sections with C4d or CD68 screening or the 
immunofluorescence of frozen sections with C3d and C4d study and the study of capillary HLA 
when possible [75]. EBM should be initiated 2 weeks post-transplantation and may be anticipated 
in sensitized patients [75]. The frequency of EBM should be performed according to the local 
transplantation center and the results obtained in the first 2 biopsies [75]. The complement study 
allows more efficient identification of those at high risk, and patients with C1q + positive in more 
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than 2 consecutive samples are associated with AMR. It is also important to note that patients 
with HLA class I or class I and II antibodies are more likely to present positive C4d 
immunofluorescence and develop rejection when compared to patients without DSA [56]. 
Detection of de novo DSA in 2/3 of the patients prior to AMR is important for the formation of 
autoantibodies involved in rejection, whereas the complement (C1q), in this case, acts as an 
adjuvant for inflammation, as observed in the Farrero study [34], which may be a new marker for 
EMB.  
2.4 Mechanical Circulatory Support 
The use of mechanical circulatory techniques such as VAD provides an improvement in 
the patient’s condition while waiting for transplantation [1, 13, 38], with VAD use increasing from 
9.1% in 2006 to 32.6% in 2017 [5]. The use of TCMS is indicated as a bridge for transplantation [1, 
36, 38] or, in the case of ACS, postcardiotomy failure, decompensated IC and primary arrhythmia 
[36]. VAD and ECMO present a poor prognosis when used in patients with CPR >30 min or with EF 
>35% [36]. There is a new generation of MCS which present a lower risk of thrombosis [5], which 
may improve the outcomes of these patients.  
ISHLT refers to the use of mechanical circulation as the possibility of reversing some 
comorbidities, such as neoplasia, where it is possible to perform the treatment before 
transplantation [51]. Regarding obesity, it allows weight loss and can be combined with bariatric 
surgery to make weight loss more efficient [76, 77], but the continuous-flow devices are 
associated with weight gain, which places these patients at a disadvantage [78, 79]. 
The use of MCS before transplantation may help predict mortality after the transplant, as 
indicated by the Johnston study [38]. The TRIP-MCS score (table 3) encompasses donor and 
recipient variables, whereas mortality was similar between the validation and derivation group 
[38]. It allows the stratification of patients according to the risk of mortality after the first year and 
allows the assessment of which patients will benefit from the transplantation or the use of VAD 
[38]. 
In a study conducted in the Netherlands, the use of VAD as a bridge for transplantation 
increases the ischemia time due to the creation of adhesions [9]. The increase in donor age 
increases the incidence of graft dysfunction, associated with an increased ischemic period, such 
as the increase in the age of the recipient due to associated pathologies [9, 68].   
PGD, most importantly related to mortality (27.1%) in the first 30 days post-
transplantation [68, 80], has like etiology the donor-recipient incompatibility and an ABO 
incompatibility [68]. It can be divided into primary dysfunction without a known cause, or 
secondary dysfunction with a known cause, such as hyperacute rejection, pulmonary 
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hypertension, among others [68]. Its diagnosis can be made through echocardiographic data 
(LVEF) and the level of ionotropic support, essential for its classification (table 8) [80]. Adequate 
treatment allows a similar survival for patients without dysfunction [68], and the use of MCS is 
recommended, with the venoarterial extracorporeal membrane (VA-ECMO) being the most used 
[68]. The use of MCS presents a worse prognosis according to the Tchantchaleishvili study [37] 
and the use of ECMO presents a good prognosis [36, 37].  
In 2015, ISHLT refers to EGF, severe PGD, with death or retransplantation associated with 
severe graft dysfunction up to 30 days post-transplantation [81]. Both donor factors (advanced 
age, cause of death non-head trauma and long duration of ischemia) and recipient factors (disease 
severity, dialysis history, use of amiodarone, creatinine or high pulmonary resistance, ventilator 
or MCS use) are associated with EGF [81]. Thus, PGD may increase in the next years and it is 
important to increase its recognition and correct treatment. 
2.5 Coronary Allograft Vasculopathy  
CAV is the main cause of long-term mortality and the most common form of chronic 
rejection [29, 45, 49]. According to ISHLT, CAV has a prevalence of 8% in the first year and 50% in 
10 years [51]. It results from the proliferation of the endothelial and smooth muscle layers, 
activation of the immune system and consequent inflammatory response and platelet activation 
[46, 48], with diffuse and progressive thickening of the intima layer of the epicardial arteries [40, 
41, 43, 44, 48]. As risk factors, we have male gender, advanced age of donor and recipient, the 
prior ischemic disease in the recipient, metabolic syndrome, smoking, CMV infection, donor CAD 
and rejection episodes [29, 47-49]. The classification is based on angiographic findings, such as the 
degree and the location of the stenosis and based on the ejection fraction of the diastolic 
dysfunction (table 9), classified as mild (CAV1), moderate (CAV2), and severe (CAV3) [39]. 
Tremblay’s study of CAV over the last 30 years has shown a reduction in its incidence, due 
to the control of risk factors such as dyslipidemia, smoking, kidney disease, use of statins, MMF 
and TAC, control of rejections, prophylaxis for infection by CMV. The use of angiography has 
decreased in recent years, and the use of non-invasive techniques, such as the echocardiogram, 
has increased [49]. This reflects the new trend in the diagnoses of CAV. 
According to ISHLT, regarding CAV, the diagnosis should be made through coronary 
angiography, stenosis value or by IVUS, through thickening of the intima (MIT), due to its high 
negative predictive value [39]. The use of IVUS greatly simplifies CAV by only detecting intimal 
proliferation and the CA normally underestimates CAV. The IVUS presents diagnostic value for the 
early phase of CAV, due to the alteration of the microvasculature [46], but also diagnostic value in 
the late phase [44]. The difficulty of the angiography in detecting CAV is due to its diffuse and 
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concentric attainment and preference for the end vessels and the stenoses which occur at a later 
stage, reducing the sensitivity of CA for CAV in an early phase [46]. Several ultrasound markers 
were proposed for the diagnosis of CAV. The CFR presents high sensitivity for the microvasculature 
dysfunction, presenting itself as an early marker for detecting CAV [46]. Because it is an invasive 
and costly procedure and is not available at all hospitals, Sade proposes the performance of CFR 
and DSE together, on an annual basis, due to high sensitivity, in order to stratify patients according 
to the risk of CAV, and if both tests are positive, a CA should be performed to study the patient, 
decreasing the side effects of CA [46]. The IMR reveals microvascular dysfunction, and IMR ≥20 is 
due to decreased cardiac output and is related to ventricular dysfunction and rejection [41]. FFR 
is related to myocardial ischemia, and when its value is >0.90 post-transplantation, it is indicative 
of the presence of donor-related atherosclerosis [41]. In his study, Yang found that both the IMR 
and FFR are related to mortality [41], and their use in the echocardiogram helps stratify the patient 
and improve their follow-up. The ASP evaluates the necrotic nucleus, fibrous tissue, and 
microcalcification existing in the CAV, presenting itself as a marker of plaque instability and 
inflammation [40]. The presence of a necrotic nucleus and plaques increases the risk of cell 
rejection and progression to CAV. The serial use of ASP allows the identification of patients at high-
risk post-transplantation, compared to classical methods [40]. The LVGLS depends on the 
longitudinal contraction of the myocardial fibers being affected by CAV, which reaches the 
epicardial vessels, decreasing LVGLS [41]. LVFP’s etiology is myocardial fibrosis caused by 
immunosuppressive treatment. The combination between LVGLS, which evaluates the VE systolic 
deformation, and LVFP, which evaluates the diastolic function, presents a synergetic value which 
allows the identification of patients at high risk for mortality [41]. OCT presents a high spatial 
resolution and allows the characterization of tissue fibrosis, calcium and lipid components [43]. 
LFP is an organized lesion resulting from the healing of a thrombus and the bright spots reflect the 
inflammatory component of CAV [43], the latter having an important role in CAV, as shown by its 
high prevalence in OCT [44]. The indicators of atherosclerosis, such as calcification and lipid 
component, remained stable throughout this study, which makes its role in CAV unimportant [43]. 
The use of OCT complements CA, being useful for patient stratification and subsequent 
therapeutic approach, but it is an invasive procedure and requires contrast. However, more 
extensive studies are needed in order to clarify the use and prognostic value of OCT [44]. The 
diagnosis of CAV through CAV is not sufficient, and the use of dobutamine and CFR 
echocardiography is the best means for diagnosis, with greater sensitivity thus reducing 
complications associated with angiography and improving results in the long-term. The use of 
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other echocardiographic markers also seems promising, however, more randomized studies are 
needed in order to understand its prognostic value.  
Immunosuppressive treatment, statins, BCC, glycaemic control, CMV prophylaxis and the 
use of antioxidants (vitamin C and E) are essential for prevention [29, 47, 48]. mTOR inhibits the 
phosphatidylinositol 3-kinase pathway, an important step in CMV replication, thereby decreasing 
its incidence [28]. In addition, it inhibits the proliferation of smooth and endothelial muscle cells 
[25, 28-30, 49, 69] but increases the value of lipids which may favor the onset of CAV [29]. In the 
Guethoff study, no relationship was found between the use of mTOR and CAV, due to the low 
concentrations of this drug [28]. In the 2013 Kobashigawa study, the replacement of MMF with 
EVR showed that the increase in MIT was lower with EVR [29]. The Watanabe study presented the 
same result, even after switching to EVR 2 years post-transplantation [30]. Thus, EVR shows 
satisfactory results in CAV, however, long-term studies are needed, in order to determine if this 
effect is prolonged.  
According to the Clemmensen study, inflammation and platelet activation are important 
factors in the etiology of CAV [43, 44]. For this purpose, the use of aspirin was studied and 
introduced in the Peled study during the first-month post-transplantation, presenting a reduction 
in the risk of CAV and mortality [47]. Long-term use is safe, and in this study, only one episode of 
hemorrhaging was reported. The 2010 ISHLT guidelines do not refer to the use of aspirin, which is 
more commonly used in patients with risk factors for CAV, as seen in the Kim study (male patients, 
smoking, and ischemic disease) [48] which may induce some effect on the results obtained in 
these studies. Despite this, the use of aspirin presents a strong protective effect of CAV and its use 
is practically universal, but clinical trials are still needed to clarify its use.  
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Key Learning Points 
Indications:  
• There is a clarity lack of evidence of study´s in this area about the main indication for HT; 
• Medium age of donor and recipient have increased in the last years and is uncertain the 
effect an outcome like the of use of marginal donor, special with advanced age;  
• Increased in the transplantation by CCMP or RT-CMP and OHT is safe but the use of MCS 
presents worst outcomes; 
• Screening test in HF patients needs more criteria to increase is power;  
• Scores for recipients and/or donors looks promising and can help the correct heart 
allocation but needs more evidence and long-term studies; 
• Is urgent change the donor exclusion policy to increase the number of transplantations;  
• Is necessary improve the long-term results of retransplantation and find more solutions 
to offer to this group of patients;  
Outcome:  
• OCS present great intermediate outcomes but is necessary a long-term evaluation; 
• mTOR is associated with proteinuria, risk of AR and severe psychological effects. More 
clinical trials are needed to evaluate his long-term effects on renal function;  
• A low dose of CNI in high-risk patients can be beneficial but no difference was found in 
renal function between mTOR/CsA and mTOR/TAC 
• The first year after transplantation needs more vigilance through EBM due to poor 
therapeutic control; 
• High-risk patients should perform EMBs periodically after the first year of transplantation; 
Patients with low risk can see their number of EMBs reduced, avoiding complications 
associated with the realization of EMB;  
• GEP, DSA de novo after HT and C1q is important for stratifying patients according to the 
risk of rejection and to decrease the use of EBM; 
• MCS is indicated as a bridge for transplantation and can reverse some comorbidities; The 
treatment of PGD included MCS and VA-ECMO IS the most used; 
• CAV is the main cause of long-term mortality and CA is the gold standard for the diagnostic 
but the IVUS is the most used. Some ultrasound markers show great results for CAV but 
are necessary more clinical validation. Inflammation is an important factor on etiology of 
CAV and Aspirin should be offered for all patients to prevent CAV; 
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Conclusion 
The reality of heart transplantation has changed tremendously in the last 50 years. A 
major change occurred with immunosuppression, with the most commonly used drugs being TAC 
and MMF, and with mTORs presenting good results in maintaining renal function and CAV, but 
with uncertain long-term results. In addition, the diagnosis of CAV presented several changes, 
whereas the use of CA may be replaced by the use of non-invasive methods such as 
echocardiography in low-risk patients. Despite this, the diagnosis of CAV is still not consensual, 
requiring more long-term studies and the search for a more sensitive test, with early detection. 
The prevention of CAV with aspirin has shown good results, but further long-term studies are 
needed. 
We currently have a high rate of recipients of advanced age and with a high rate of 
comorbidities, which may compromise the long-term results of HT. Thus, we must continue to 
work in improving the survival rate that has stagnated in recent years. The approach of these 
patients will need to be reviewed so that transplantation remains the gold standard therapy, and 
it is also necessary to address the age of the patient and their comorbidities.  
In this review, there is a lack of information regarding the indications for transplantation, 
and more studies are also necessary here, in order to understand what type of patients we have 
as candidates and how we can reduce the waiting time by creating more scores adjusted to the 
reality of these patients. MCS as a therapeutic bridging aid also requires further investigation 
regarding the effects on survival.  
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Annexes 
Table 1:  IMPACT Score adapted from Weiss et al 2011 [16] 
 Points assigned 
Age >60 years 3 
Bilirubin  
   1-1,99 1 
   2-3,99 3 
   ≥4 4 
Creatinine Clearance  
   30-49 mL/minute 2 
   <30 mL/minute 5 
   Dialysis between listing and transplant 4 
Female sex 3 
Heart Failure etiology  
   Ischemic 2 
  Congenital 5 
   Other 1 
Infection 3 
IABP 3 
Mechanical ventilation prior to transplant 5 
Race  
   African American 3 
Temporary circulatory support 7 
VAD  
   Older gen pulsatile 3 
   New Gen continuous  5 
Total points possible 50 
 
Legend: IABP: intra-aortic balloon pump; 
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Table 2:  Score adapted from Trivedi et al 2016 [17] 
 Points assigned 
Donor factors 
Donor age (years)  
   50-55 1 
   >55 2 
Ischemic time >4 hours 2 
Gender mismatch 1 
Diabetes 1 
Total donor allowed 6 
Low risk: 0 points 
Intermediate risk: 1,2 points 
High risk:  ≥3 points 
Recipient Factors 
Age> 65 years 1 
BMI kg/m2  
  30-35 1 
   ≥35 2 
Mean pulmonary artery pressure >30 2 
Total bilirubin  
   1,5-1,9 2 
   >1,9 2 
Creatinine  
   1,5-2,0 1 
   >2,0 2 
Previous transplant 2 
Previous cancer 2 
Ventilator 2 
Mechanical circulatory support 2 
Total recipients allowed 16 
Very low risk: 0 points 
Low risk: 1 point 
Intermediate risk: 2 points 
High risk: 3,4 points 
Very high risk ≥5 points 
Legend: BMI: body mass index; 
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Table 3: TRIP-MCS score adapted from Johnston et al 2016 [38] 
 Points allocated 
Recipient Variable 
Age>60 yrs 7 
BMI, Kg/m2  
   25-34 5 
   ≥34 10 
Total bilirrubin >1,0 md/dL  5 
Estimated GFR <50 mL/min/1,73 m2 10 
Any dialysis since listing 6 
Mechanical ventilation at the time of 
transplantation 
10 
Admitted to ICU at time of transplantation 3 
Recently treated infection 4 
Type of circulatory support  
   Other anatomic position than LVAD or 
additional support, excluding ECMO 
3 
Donor Variables 
Age > 40 yrs 3 
Sex mismatch with the recipient 4 
Inchemic time > 4h 5 
Estimated GFR < 50 mL/min/1,73 m2 5 
Total possible score 15 
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Table 4: Indications and contraindications adapted from ISHLT-WF 2006 and 2016  [51, 52] 
Legend: BMI: Body mass Index; HbA1c: glycosylated hemoglobin; PVR: pulmonary vascular resistance; 
 
 
 2006 2016 
Acceptable Candidates 
 VO2≤14mL/Kg/min; Continuing approval without 
change; 
 Respiratory Exchange Ratio 
>1,05 with the achievement of 
anaerobic metabolism; 
Continuing approval without 
change; 
 - HF prognosis score ( SHFM<80% 
and HFSS in the médium/high 
risk); 
 -  Signficant CAV without evidence 
of rejection (retransplant); 
Probable Candidates 
 Age>70 years should be 
considered other programs;  
Age>70 years should be 
considered, carefully 
 Pre-existing malignancies 
should be considered when 
tumor recurrence is slow based 
on tumor type, response to 
therapy, and negative 
metastatic work-up; 
Continual approval without 
change; 
Absolute Contraindication 
 BMI >30 Kg/m2; BMI >35 Kg/m2; 
 -  Clinical severe symptomatic 
cerebrovascular disease; 
 -  Frailty (3 of 5 symptoms: 
unintentional weight loss of ≥4,5 
Kg within the past year, muscle 
loss, slow walking speed and low 
levels of physical activity); 
 Active smoker (<6 months since 
quitting) and active substance 
abusers (including alcohol); 
Continuing approval without 
change; 
Relative Contraindication 
 Diabetes with end-organ 
damage other than nom-
proliferative retinopathy, 
HbA1c>7,5%; 
Diabetes with end-organ 
damage other than nom-
proliferative retinopathy, 
HbA1c>7,5% or 58 mmol/mol; 
 GFR <40 mL/mim/1,73 m2; GFR <30 mL/mim/1,73 m2; 
   
 Peripheral vascular disease; Continuing approval without 
change; 
 Clinical severe symptomatic 
cerebrovascular disease; 
-  
 Mental retardation or 
dementia;  
Mental retardation, dementia or 
insufficient social support;   
 Pulmonary artery hypertension 
and elevated PVR;   
Continuing approval without 
change; 
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Table 5: Marginal heart donors: criteria for non-use in France (France) adapted from Dorent et al 
2018 [64] 
Age > 70 years; 
Unknown cause of brain death; 
Myocardial Contusion; 
Intractable ventricular arrhythmias; 
Hemodynamic Instability with high-dose of inotropes; 
Catecholamine support advice aggressive hemodynamic management; 
Persistent LVEF<40%; 
Diastolic left ventricular Wall thickness ≥16 mm; 
Severe valvular/Congenital lesions; 
Obstructive coronary artery disease in any major coronary artery; 
 
Table 6: Exclusion criteria for Donor selection in the USA based on guidelines from Society 
Critical Care Medicine [66] 
Presence of functional and morphologic cardiac disease; 
Advanced donor age (>55 years); 
Mismatch of donor/recipient size; 
Previous cardiac arrest (>20 min); 
Significant thoracic trauma; 
LVH (Wall thickness >1,4 cm); 
Echocardiography and CA in patients > 40 years or young donors with risk factors for CAD; 
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Table 7: Current status codes for heart transplant allocation adapted from UNOS [72] 
Status 1 VA-ECMO; 
Nom-dischargeable, surgically implanted, nom-
endovascular LVAD; 
MCSD with life-threatening ventricular arrhythmia 
Status 2 Nom-dischargeable, surgically implanted, nom-
endovascular LVAD; 
IABP; 
MCSD with device malfunction/mechanical failure; 
BiVAD, RVAD or VAD for single ventricle patients; 
Percutaneous endovascular MCSD 
Status 3  Dischargeable LVAD for discretionary 30 days; 
Multiple inotropes or single high-dose inotrope with 
continuous hemodynamic monitoring; 
VA-ECMO after 7 days; percutaneous endovascular 
circulatory support device or IABP after 14 days; 
Non-dischargeable, surgically implanted, non-
endovascular LVAD after 14 days; 
MCSD with one of the following: device infection, 
hemolysis, pump thrombosis, right heart failure, mucosal 
bleeding, and aortic insufficiency; 
Status 4 Dischargeable LVAD without discretionary 30 days; 
Inotropes without hemodynamic monitoring; 
Retransplant; 
 Diagnosis of one of the following: congenital heart 
disease (CHD), ischemic heart disease with intractable 
angina, hypertrophic cardiomyopathy, restrictive 
cardiomyopathy, and amyloidosis; 
Status 5 On the waitlist for at least one other organ at the same 
hospital; 
Status 6 All remaining active candidates; 
 
Legend: BiVAD: biventricular assist device; IABP: intra-aortic balloon pump; 
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Table 8: Classification of PGD adapted from ISHLT-WF 2014 [80] 
PGD- Left ventricle (PGD-LV) Mild PGD-LV: one of the 
following criteria must be met: 
LVEF ≤40% by 
echocardiography, or: 
CI<2,0 L/min/m2 (lasting more 
than 1 hour) requiring low-dose 
inotropes;  
 
Moderate PGD-LV: must meet 
one criteria from I and another 
criteria from II 
I. One criteria from 
the following: 
Left ventricular ejection fraction 
≤40%, or 
Hemodynamic compromise 
with RAP>15 mm Hg, PCWP>20 
mm Hg, CI<2,0 L/min/m2, 
hypotension with MAP<70 mm 
Hg (lasting more than 1 hour); 
II. One criteria from 
the following: 
High dose inotropes;  
Newly placed IABP; 
PGD- Right Ventricle (PGD-RV) Severe PGD-LV Dependence on left or 
biventricular mechanical 
support including ECMO, LVAD, 
BiVAD, or percutaneous LVAD. 
Excludes requirement for IABP. 
i. Hemodynamics 
with RAP>15 mm 
Hg, PCWP<15 mm 
Hg, CI<2,0 
L/min/m2 
ii. TPG<15 mm Hg 
and/or Pulmonary 
artery systolic 
pressure < 50 mm 
Hg, or 
iii. Need for RVAD 
Diagnoses requires either both 
i, ii or iii alone: 
 
Legend: BiVAD: biventricular assist device; CI: cardiac index; IABP: intra-aortic balloon pump; PCWP, 
pulmonary capillary wedge pressure; RAP, right atrial pressure; TPG: transpulmonary pressure gradient; 
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Table 9: CAV classification adapted from 2010 ISHLT-WF [39] 
CAV0 (Not significant) No detectable angiographic lesions; 
CAV1 (Mild) Angiographic left main (LM) <50% or primary 
vessel with maximum lesion of <70% or any 
branch stenosis <70% (including diffuse 
narrowing) without allograft dysfunction; 
CAV2 (Moderate) Angiographic LM <50%; a single primary vessel 
≥70% vessel, or isolated branch stenosis ≥70% in 
branches of 2 systems, without allograft 
dysfunction; 
CAV3 (Severe) Angiographic LM ≥50%, or two or more primary 
vessels ≥70% stenosis, or isolated branch 
stenosis ≥70% in all 3 systems; or ISHLT CAV2 or 
CAV 2 with allograft dysfunction (defined as LVEF 
≤45% usually in the presence of regional wall 
motion abnormalities) or evidence of significant 
restrictive physiology;  
 
 
 
